Prostate Cancer clinical trials in Rhode Island

6 actively recruiting prostate cancer trials at 2 sites across Rhode Island.

Data from ClinicalTrials.gov · last refreshed 2026-08-10

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group

NCT ID: NCT06592924

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island
Miriam Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05806515

Sites in Rhode Island:

Smilow Cancer Hospital Care Center - Westerly — Westerly, Rhode Island

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 …

Sponsor: AstraZeneca

NCT ID: NCT07192614

Sites in Rhode Island:

Research Site — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants …

Sponsor: Hoffmann-La Roche

NCT ID: NCT07287150

Sites in Rhode Island:

Lifespan Cancer Institute — Providence, Rhode Island

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…

Sponsor: Janux Therapeutics

NCT ID: NCT05519449

Sites in Rhode Island:

Rhode Island Hospital — Providence, Rhode Island

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Rhode Island:

Massive Bio SYNERGY-AI site — Providence, Rhode Island

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-10